Resources
116 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
Adopting a Shared Framework for Community Collaboration Webinar and Resources
Posted 11/19/2019 (updated 3/25/2024)
Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device.
Posted 12/22/2021 (updated 3/26/2024)
This guide provides rural health care leaders and teams with foundational knowledge, strategies, and resources to understand the impact of social determinants of health (SDOH) on patients and communities. It organizes key information and resources to help the busy manager support and lead education and discussion with front-line staff. This guide focuses on (1) understanding the need and opportunity around addressing SDOH, (2) using local data to support decision making, and (3) involving team members to plan and implement action steps.
Posted 7/26/2023 (updated 3/26/2024)
During this session, the Rural Behavioral Health Workforce Centers (RBHWCs) shared their collaborative project: a central resource hub for new workers looking to join the behavioral health workforce and a marketing campaign centering the value and roles of peer supports.
Posted 6/27/2023 (updated 3/26/2024)
This webinar will describe ways to explore social determinants of health (SDOH) and exemplify challenges/ opportunities in Rural America.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 7/31/2023 (updated 3/26/2024)
This presentation will cover health equity regarding rural American Indian and Alaska Native (AI/AN) communities' prevention and treatment efforts to address substance use disorder (SUD), including the need for contingency management for stimulants.
Posted 7/31/2023 (updated 3/26/2024)
In this webinar, the presenters discussed these numerous factors affecting social determinants of health (SDOH) and health outcomes, particularly in these communities, and strategies to address them.
Posted 3/3/2022 (updated 3/26/2024)
The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programs, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).